JenaValve Technology
Dr. Andrew Hack has served as Managing Director at Bain Capital Life Sciences since 2019. Andrew currently serves on our Board of Directors and is a member of our Compensation Committee and chairman of our Audit Committee.
Dr. Hack previously served for as Chief Financial Officer of Editas Medicine (Nasdaq: EDIT) and as a healthcare portfolio manager at Millennium Management. Prior to that, he was a securities analyst at a number of healthcare-focused hedge funds and investment banks.
Dr. Hack received an MD and a PhD in molecular genetics and cell biology from the University of Chicago.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
JenaValve Technology
1 followers
JenaValve Technology develops transcatheter aortic valve implantation (TAVI) systems for transapical and transfemoral implantation.